Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Dermavant Sciences GmbH is currently managing 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 3 distinct examiners and 3 distinct art units. This distribution indicates that each pending matter is being reviewed by a different examiner in a separate technical group. With 3 distinct art units involved, the portfolio faces scrutiny from multiple specialized groups within the office. This diversity in examination requires a strategy that addresses the specific tendencies of 3 different examiners across various technical classifications within the Biotechnology & Pharmaceuticals sector.
The busiest examiner for the company is SEITZ, ANTHONY JOSEPH, who is responsible for 1 pending office action. Because there are 3 pending office actions and 3 distinct examiners, each examiner is assigned 1 action. This lack of concentration means that no single examiner has a disproportionate influence on the company's pending matters. Practitioners should focus on the individual requirements of each of the 3 distinct examiners. The spread across 3 distinct art units suggests that the company's technology in the Biotechnology & Pharmaceuticals sector is technically diverse.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NGUYEN, JOHN P | 1 | 43.9% | +41.8% |
| COPPINS, JANET L | 1 | 72.6% | +26.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18066945 | TOPICAL PHARMACEUTICAL COMPOSITIONS | NGUYEN, JOHN P | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18066945 | TOPICAL PHARMACEUTICAL COMPOSITIONS | NGUYEN, JOHN P | — |
| 17820692 | REMITTIVE EFFECTS OF TAPINAROF IN THE TREATMENT OF PLAQUE PSORIASIS, ATOPIC DERMATITIS, OR RADIATION DERMATITIS | COPPINS, JANET L | — |
| Art Unit | Apps |
|---|---|
| 1619 | 1 |
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18066945 | TOPICAL PHARMACEUTICAL COMPOSITIONS | NGUYEN, JOHN P | 1619 | §103§112 | Final Rejection | — | Pending | Dec 15, 2022 |
| 17820692 | REMITTIVE EFFECTS OF TAPINAROF IN THE TREATMENT OF PLAQUE PSORIASIS, ATOPIC DERMATITIS, OR RADIATION DERMATITIS | COPPINS, JANET L | 1628 | §112 | Non-Final OA | — | Pending | Aug 18, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDermavant Sciences GmbH has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
John P Nguyen has the most, with 1 of Dermavant Sciences GmbH's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
